hyperCORE International Strengthens Executive Leadership with New Vice President and Treasurer Appointments

hyperCORE International, a leading collaborative network of clinical trial sites across North America, has announced significant updates to its executive leadership team with the appointment of Jeffrey Smyth as Vice President and Olivia McIver as Treasurer. These strategic additions strengthen the organization's governance structure and ensure continued alignment with hyperCORE's mission of driving efficiency and excellence across its collective partner site networks.

Jeffrey Smyth brings substantial experience to his new role as Vice President, currently serving as President and Executive Director of partner site network TrueBlue Clinical Research. Olivia McIver joins as Treasurer, bringing her expertise from her position as Director of Clinical Operations at partner site network Applied Research Center. The complementary expertise these executives bring will support hyperCORE's growth initiatives and play a crucial role in overseeing financial stewardship while supporting long-term sustainability for the organization.

Nicholas Focil, President of hyperCORE, emphasized the strategic importance of these appointments, stating that the organization's strength lies in its ability to unify best-in-class research sites through shared operational excellence. As hyperCORE continues to expand, having a dedicated Vice President and integrated board Treasurer becomes essential to guide the leadership framework and maintain strategic mobility across the clinical research industry.

The executive leadership team maintains continuity with Nicholas Focil, CEO of FOMAT Medical Research, continuing to serve as President, and Mark Scullion, CEO of Atlas Clinical Research, remaining in his role as Secretary. This experienced leadership team will guide hyperCORE through its next phase of growth and development.

hyperCORE International represents a powerful network of clinical research site organizations, with partner networks including AGA Clinical Trials, Alcanza Clinical Research, Apex Trials, Applied Research Center, Atlas Clinical Research, CaRe Clinics, Epic Medical Research, FOMAT Medical Research, TrueBlue Clinical Research, and QCR Network. Each network operates independently while participating in harmonized operational frameworks that streamline study delivery at scale, creating significant efficiencies for pharmaceutical companies and research sponsors.

The organization's impressive scale includes over 80 active trial sites across five countries and two continents, with partners having collectively completed more than 7,500 studies involving over 150,000 randomized participants. This extensive experience and geographic reach position hyperCORE as a significant force in the clinical research landscape, capable of accelerating drug development timelines and improving research outcomes through standardized operational frameworks.

For the clinical research industry, these leadership appointments signal hyperCORE's commitment to maintaining its position as a leader in collaborative research networks. The enhanced governance structure provides greater stability and strategic direction for partner sites, which could translate to improved study performance, faster patient enrollment, and higher quality data collection for clinical trials. Pharmaceutical companies and research sponsors benefit from working with a unified network that maintains consistent operational standards across multiple geographic locations.

hyperCORE remains dedicated to advancing clinical research through safe, ethical, and timely studies, with a focus on efficient enrollment and superior retention rates. The organization's members have earned top-tier awards for performance, quality, and innovation, further strengthening the network's reputation for excellence in clinical research execution. These leadership enhancements come at a time when the clinical research industry faces increasing pressure to accelerate drug development while maintaining rigorous quality standards, making hyperCORE's collaborative approach particularly valuable for addressing these challenges.